Koch-WeserJ.: Antiarrhythmic Prophylaxis in Ambulatory Patients with Coronary Heart Disease, Arch. Intern. Med.129: 763–772 (May) 1972.
2.
AmsterdamE. A.MassumiR. A.ZelisR.MasonD. T.: Use of Bretylium Tosylate in the Management of Cardiac Arrhythmias, Heart Lung1: 269, 1972.
3.
SinghB. N.WilliamsE. M. Vaughan: Local Anesthetic and Antiarrhythmic Actions of Alprenolol Relative to its Effect on Intracellular Potentials and Other Properties of Isolated Cardiac Muscle, Br. J. Pharmacol38: 749–757 (Apr.) 1970.
4.
SinghB. N.WilliamsE. M. Vaughan: The Effect of Amiodarone, a New Antianginal Drug on Cardiac Muscle, Br. J. Pharmacol.39: 657–667, 1970.
5.
SinghB. N.WilliamsE. M. Vaughan: A Third Class of Antiarrhythmic Action. Effect on Atrial and Ventricular Potentials, and Other Pharmacological Actions on Cardiac Muscles, of MJ1999 and AH3474, Br. J. Pharmacol.39: 676–687, 1970.
6.
SinghB. N.: Antiarrhythmic Action of β-adrenergic Receptor Antagonists: Review of Fundamental Aspects, N. Z. Med. J.76: 333–342 (Nov.) 1972.
7.
SinghB. N.: Clinical Aspects of the Antiarrhythmic Action of β-receptor Antagonist, N. Z. Med. J.78: 482, 1973.
8.
SchamrothL.: Immediate Effects of Intravenous Verapaniel on Atrial Fibrillation, Cardiovasc. Res.5: 419–424, 1971.
9.
PolsterP.WilliamsE. M. Vaughan: The Prolonged Treatment with Oxyfedrine on Intracellular Potentials and on Other Features of Cardiac Function in Rabbits and Guinea Pigs, Br. J. Pharmacol.47: 187–195 (Feb.) 1973.
10.
Norpace® capsules, Brand of Disopyramide Phosphate, Company Drug Literature, Searle Laboratories (Aug.) 1977.
11.
JenningsG.JonesM. B. S.BestermanE. M. M.ModelD. G.TurnerP. P.KidnerP. H.: Oral Disopyramide in Prophylaxis of Arrhythmias Following Myocardial Infarction, Lancet1: 51–54 (Jan.) 1976.
12.
MizgalaH. F.HuvelleP. R.: Acute Termination of Cardiac Arrhythmias with Intravenous Disopyramide, J. Int. Med. Res.4: (suppl. 1) 82–85, 1976.
13.
SpurrellR. A. J.ThorburnC. W.CammJ.SowtonE.DeucharD. C.: Effects of Disopyramide on Electrophysiological Properties of Specialized Conduction System in Man and on Accessary Atrioventricular Pathway in Wolff-Parkinson-White Syndrome, Br. Heart J.37: 861–867, 1975.
14.
SlomanJ. G.HuntD.VohraJ.DowlingJ.DuffieldA.: Oral Disopyramide in the Management of Cardiac Arrhythmias, Med. J. Aust.1: 176–180 (Feb. 5) 1977.
15.
ZainalN.GriffithsJ. W.CarmichaelD. J. S.BestermanE. M. M.KidneyP. H.GillhanA. D.SummersG. S.: Oral Disopyramide for the Prevention of Arrhythmias in Patients with Acute Myocardial Infarction Admitted to Open Wards, Lancet2: 887–889 (Oct. 29) 1977.
16.
HartellG.LouhijaA.KonttinenA.: Disopyramide in the Prevention of Atrial Fibrillation after Electroconversion, Clin. Pharmacol. Ther.15: 551–555 (June) 1974.
17.
SinghB. N.HauswirthO.: Comparative Mechanisms of Action of Anti-arrhythmic Drugs, Am. Heart J.87: 367–382 (Mar.) 1974.
18.
CaractaA.: The Electrophysiology of Norpace® (Part III), Angiology26: (suppl. 1) 120–123, 1975.
19.
DeanR. R.: The Pharmacology of Norpace®, Angiology26: (suppl. 1) 67–84, 1975.
20.
DeanR. R.FergusonD. M.: Effects of Disopyramide on the A-V Conduction System, Arch. Int. Pharmacodyn. Ther.190: 183–186, 1971.
21.
DreifusL. S.FilipZ.SextonD. M.: Electrophysiological and Clinical Effects of a new Anti-arrhythmic Agent: Disopyramide, Am. J. Cardiol.31: 129, 1973.
22.
NaylerW. G.: The Pharmacology of Disopyramide, J. Int Med Res.4: (suppl. 1) 8–12, 1975.
23.
VismaraL. A.VeraZ.MillerR. R.MasonD. T.: Efficacy of Disopyramide Phosphate in the Treatment of Refractory Ventricular Tachycardia, Am. J. Cardiol.39: 1027–1034 (June) 1977.
24.
DaniloP.Jr.RosenM. R.: Cardiac Effects of Disopyramide, Am. Heart J.92: 532–536 (Oct.) 1976.
25.
BefelerB.CostellanosA.WellsD. E.VagnerioM. D.YehB. K.: Electrophysiologic Effects of the Anti-arrhythmic Agent Disopyramide Phosphate, Am. J. Cardiol.35: 282–287, 1975.
26.
DeanoD. A.WuD.MautnerR. K.ShermanR. H.EhsaniA. E.RosenK. M.: The Antiarrhythmic Efficacy of Intravenous Therapy with Disopyramide Phosphate, Chest71: 597–606 (May 5) 1977.
27.
KarimA.: The Pharmacokinetics of Norpace®, Angiology26: 85–98, 1975.
ChienY. W.LambertH. J.KarimA.: Comparative Binding of Disopyramide Phosphate and Quinidine Sulfate to Human Plasma Proteins, J. Pharm. Sci.63: 1877–1879 (Dec.) 1974.
30.
MathurP. P.: Cardiovascular Effects of a Newer Antiarrhythmic Agent, Disopyramide Phosphate, Am. Heart J.84: 764–770, 1972.
31.
VismaraL. A.DeMariaA. N.MillerR. R.: Effects of Intravenous Disopyramide Phosphate on Cardiac Function and Peripheral Circulation in Ischemic Heart Disease, Clin. Res.23: 87, 1975.
32.
CunninghamJ. L.ShenD. D.ShudoI.AzarnoffD. L.: The Effects of Urine pH and Plasma Protein Binding on Renal Clearance of Disopyramide, Clin. Pharmacokinet.2: 373–383, 1977.
33.
JosephsonM. E.CaractaA. R.LauS. H.: Electrophysiological Evaluation of Disopyramide in Man, Am. Heart J.86: 771–780, 1973.
34.
BirkheadJ. S.WilliamsE. M. Vaughan: Dual Effect of Disopyramide on Atrial and Atrioventricular Conduction and Refractory Periods, Br. Heart J.39: 657–660, 1977.
35.
AbramowiczM., (Ed.): Disopyramide (Norpace®) for Ventricular Arrhythmias, The Medical Letter19 (25): 101–102 (Dec. 16) 1977.
DaniloP.Jr.HordofA. J.RosenM. R.: Effects of Disopyramide Phosphate (Norpace®) on Electrophysiologic Properties of Isolated Canine Cardiac Purkinje Fibers, Am. J. Cardiol.35: 130 (Jan.) 1975.
WardJ. W.KinghornG. R.: The Pharmacokinetics of Disopyramide Following Myocardial Infarction with Special Reference to Oral and Intravenous Dose Regimens, J. Int Med. Res.4: (suppl. 1): 49–53, 1976.
47.
FriedenJ.: Quinidine Effects Due to Disopyramide, New Engl J. Med.298: 925 (Apr. 27) 1978.
